Cost-effectiveness of Pazopanib Versus Sunitinib as First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma from an Italian National Health Service Perspective
Authors:
- 1 March 2017
- journal article
- research article
- Published by Elsevier in Clinical Therapeutics
- Vol. 39 (3) , 567-580.e2
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Utility values among patients (pts) with metastatic renal cell carcinoma (mRCC) receiving first-line treatment with pazopanib (PZ) and sunitinib (SU).Journal of Clinical Oncology, 2016
- Overall Survival in Renal-Cell Carcinoma with Pazopanib versus SunitinibNew England Journal of Medicine, 2014
- Pazopanib versus Sunitinib in Metastatic Renal-Cell CarcinomaNew England Journal of Medicine, 2013
- Quality of life (QoL) among patients with renal cell carcinoma (RCC) treated with pazopanib versus sunitinib in the COMPARZ study.Journal of Clinical Oncology, 2013
- The Epidemiology of Renal Cell CarcinomaEuropean Urology, 2011
- Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III TrialJournal of Clinical Oncology, 2010
- Estimates of the Incidence and Prevalence of Renal Cell Carcinoma in Italy in 2002 and Projections for the Years 2007 and 2012Tumori Journal, 2009
- Blinded Independent Central Review of Progression-Free Survival in Phase III Clinical Trials: Important Design Element or Unnecessary Expense?Journal of Clinical Oncology, 2008
- Renal-Cell CarcinomaNew England Journal of Medicine, 2005
- Estimating Medical Costs from Incomplete Follow-Up Data1997